A longitudinal study of human antibody responses to Plasmodium falciparum rhoptry-associated protein 1 in a region of seasonal and unstable malaria transmission by Fonjungo, P.N. et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A longitudinal study of human antibody responses to
Plasmodium falciparum rhoptry-associated protein 1 in a region
of seasonal and unstable malaria transmission
Citation for published version:
Fonjungo, PN, Elhassan, IM, Cavanagh, D, Theander, TG, Hviid, L, Roper, C, Arnot, DE & McBride, JS
1999, 'A longitudinal study of human antibody responses to Plasmodium falciparum rhoptry-associated
protein 1 in a region of seasonal and unstable malaria transmission' Infection and Immunity, vol. 67, no. 6,
pp. 2975-2985. DOI: No DOI for this publication.
Digital Object Identifier (DOI):
No DOI for this publication.
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Infection and Immunity
Publisher Rights Statement:
RoMEO blue
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
INFECTION AND IMMUNITY,
0019-9567/99/$04.0010
June 1999, p. 2975–2985 Vol. 67, No. 6
Copyright © 1999, American Society for Microbiology. All Rights Reserved.
A Longitudinal Study of Human Antibody Responses to Plasmodium
falciparum Rhoptry-Associated Protein 1 in a Region of
Seasonal and Unstable Malaria Transmission
PETER N. FONJUNGO,1† IBRAHIM M. ELHASSAN,2,3 DAVID R. CAVANAGH,1 THOR G. THEANDER,2
LARS HVIID,2 CALLY ROPER,1,4 DAVID E. ARNOT,1 AND JANA S. MCBRIDE1*
Institute of Cell, Animal and Population Biology, University of Edinburgh, Edinburgh EH9 3JT, Scotland1; Centre for Medical
Parasitology at the Institute for Medical Microbiology and Immunology, University of Copenhagen and RHIMA Centre,
Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark2; Institute of Endemic Diseases,
University of Khartoum, Khartoum, Sudan3; and Department of Infectious and Tropical Disease,
London School of Hygiene and Tropical Medicine, London, England4
Received 26 October 1998/Returned for modification 15 December 1998/Accepted 26 March 1999
Rhoptry-associated protein 1 (RAP1) of Plasmodium falciparum is a nonpolymorphic merozoite antigen that
is considered a potential candidate for a malaria vaccine against asexual blood stages. In this longitudinal
study, recombinant RAP1 (rRAP1) proteins with antigenicity similar to that of P. falciparum-derived RAP1
were used to analyze antibody responses to RAP1 over a period of 4 years (1991 to 1995) of 53 individuals
naturally exposed to P. falciparum malaria. In any 1 year during the study, between 23 and 39% of individuals
who had malaria developed immunoglobulin G (IgG) antibodies detectable with at least one rRAP1 protein.
However, the anti-RAP1 antibody responses were detected only during or shortly after clinical malarial
infections. RAP1 antibody levels declined rapidly (within 1 to 2 months) following drug treatment of the
infections. No anti-RAP1 antibodies were usually detected a few months after the end of malaria transmission,
during the dry season, or by the start of the next malaria season. Thus, RAP1 IgG responses were very
short-lived. The short duration of RAP1 antibody response may explain the apparent lack of response in a
surprisingly high proportion of individuals after clinical malarial infections. For some individuals who
experienced more than one malarial infection, a higher anti-RAP1 antibody response to subsequent infections
than to earlier infections was observed. This suggested secondary responses to RAP1 and thus the development
of immunological memory for RAP1.
Malaria remains a major infectious disease in many parts of
the tropics. It is estimated that over 300 to 500 million clinical
cases occur each year, with cases in tropical Africa accounting
for more than 90% of these figures (52). Infection by Plasmo-
dium falciparum of individuals who have not been exposed to
malaria before invariably leads to the disease. The infection
can, however, become clinically less severe in individuals living
for several years in regions where malaria is endemic. Two
situations have been observed, seemingly dependent on dis-
tinct epidemiological patterns of, and thus exposure to, malaria
(28, 31). First, in populations with a low frequency of the
infection due to unstable transmission the development of
acquired immunity is often incomplete. In this situation, it is
believed, most infections in all age groups are likely to develop
into the disease. Second, in populations in which malaria trans-
mission is frequent and stable, acquired immunity does de-
velop, though over a long period of time. In this situation,
clinical disease is more frequent in children than in adults,
presumably because children have not yet received the re-
peated exposure believed to be required to achieve the level of
immunity shown by the adults in the same community.
There is no clear understanding of the mechanism(s) of this
naturally acquired immunity in humans. Nonetheless, it is
known that the immunity is partly mediated by antibodies since
passive transfers of purified immunoglobulin G (IgG) from
immune adult West Africans to P. falciparum-infected patients
rapidly reduced the recipients’ parasitemia (8, 32, 41). The
identification of parasite antigens that induce protective anti-
body responses would be an important step toward the under-
standing of naturally acquired human immunity to malaria. In
this context, it is particularly pertinent to understand the de-
velopment of human responses to several defined merozoite
antigens now considered as targets for the development of a
blood-stage vaccine because of their ability to induce partial or
complete protection against parasite challenge in animal mod-
els (21). Importantly, naturally occurring human antibodies to
certain merozoite antigens have been correlated with reduced
parasite densities or disease by seroepidemiological studies.
For example, antibodies detectable with recombinant MSP1
(rMSP1) or P. falciparum MSP1 (10, 51), rMSP2 (1, 49), or
rRESA (2) were correlated with lower parasite densities. The
results indicate a protective role for antibodies to these anti-
gens, and such field studies on naturally occurring immune
responses of humans thus complement animal experiments
conducted for the purposes of vaccine development.
Rhoptry-associated protein 1 (RAP1), the subject of this
study, is considered an important malaria vaccine antigen.
Since the amino acid sequence of RAP1 shows only very lim-
ited diversity among P. falciparum isolates (17, 19, 20, 37),
antigenic polymorphism should be less of a problem for a
RAP1 vaccine than for vaccines based on some other, more
polymorphic antigens of the parasite. Immunizations with af-
finity-purified protein complex containing RAP1 modified the
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course of parasitemia and protected Saimiri monkeys from a
lethal P. falciparum challenge infection (36). In vitro, mono-
clonal and polyclonal antibodies to P. falciparum RAP1 inhibit
merozoite invasion (16, 18, 42, 45), suggesting that antibodies
to RAP1 may reduce parasite multiplication. Now it is impor-
tant to elucidate the natural development of infection-induced
human immune responses to RAP1.
Anti-RAP1 antibodies have been detected in people living in
different regions where malaria is endemic (13, 19, 22–24, 46);
thus, RAP1 is antigenic and a target for human immune re-
sponses. It has further been shown that most of the detectable
human antibodies are of the IgG1 subclass (13) and are tar-
geted to N-terminal parts of RAP1 (13, 19). Importantly, an
association between high levels of IgG antibodies to the N-
terminal regions of RAP1 and protection against high densities
of P. falciparum parasites in Tanzanian children (25) has sug-
gested a possible role of anti-RAP1 antibodies in human im-
munity. All these studies were cross-sectional surveys evaluat-
ing RAP1 antibodies at one point in time. Since no study has
monitored individuals longitudinally, so far it has not been
possible to approach even relatively simple questions about the
dynamics of anti-RAP1 responses. Thus, it is not known how
reliably antibodies to RAP1 are produced in response to a
malarial infection, or what may be the duration of anti-RAP1
responses after the infection.
In this study, immunologically well characterized rRAP1
proteins (13) were used to analyze for the first time longitudi-
nal antibody responses to RAP1 in individuals exposed to
naturally transmitted P. falciparum infections over a period of
several years. We have investigated the frequency of antibody
responses to RAP1 following documented clinical infections,
the duration of these responses after drug treatment of pa-
tients, and the question whether immunological memory to
RAP1 is detectable after reinfections.
MATERIALS AND METHODS
Study area. This longitudinal study was carried out among permanent resi-
dents of Daraweesh, a small sorghum and sesame farming village in Gedaref
State, 450 km southeast of Khartoum, Sudan. The main vector responsible for
transmission is Anopheles arabiense (15, 26), and P. falciparum is the predomi-
nant malarial species (3, 39). The climate is characterized by annual rainfalls
between July and September, with a very dry season for the rest of the year.
Clinical malaria cases occur in residents of Daraweesh from about September to
November and peak in October or November. The period when clinical cases are
observed, termed malaria season in this study, normally begins in September and
ends by January in most years (40, 50). However, the region has been described
as having seasonal and unstable malaria transmission (11, 12). The instability of
malaria was demonstrated during a severe drought, October 1989 to June 1992,
which interrupted malaria transmission in Daraweesh for 2 years, with fewer than
10 cases found in the entire village during the 1990–1991 and 1991–1992 seasons
(39).
Study cohort, malaria monitoring, and collection of samples. The village has
a population of approximately 430 inhabitants, most of whom are descendants of
a Fulani group, originally from Burkina Faso, who settled in Sudan a century ago.
The residents of Daraweesh have participated in a study of acquired immunity to
P. falciparum since 1988. This longitudinal study was carried out in a cohort of 53
permanent residents (born 1963 to 1987), from September 1991 to January 1995.
The sickle cell hemoglobin trait was absent from all individuals involved in the
study (50). The project had an ethical clearance from the Research Board of the
Faculty of Medicine, University of Khartoum, and a national clearance granted
by the Sudanese Ministry of Health.
All individuals involved in the cohort study were monitored for malaria each
year from the beginning of September until the following mid-January as de-
scribed in detail elsewhere (11, 39, 40). Malaria detection was carried out
through a clinic run in the village by the project’s health team at least every
second day. A health worker resident in the village was available for consultation
daily. Active case detection was performed by health assistants on house visits to
the cohort members every 2 weeks. Each individual was questioned about any
illness since the previous visit, and oral temperature was measured; if the tem-
perature was higher than 37.5°C or if the individual complained of fever, Giemsa-
stained blood film was prepared. Passive case detection involved individuals who
reported to the health team with any symptoms suggestive of malaria (constant
or intermittent fever, headache, joint pain, vomiting, and diarrhea). The oral
temperature of such individuals was measured, and blood film was examined. In
this study, clinical malaria was defined as a febrile illness with P. falciparum-
positive blood film and a body temperature of 37.5°C, or a positive blood film and
reported complaint of fever. During the 1991 malaria season, both active and
passive case detection methods were used, but no cases were detected that
season. In the subsequent years, only passive case detection was used; thus, all
cases reported in this study were detected passively. Chloroquine was adminis-
tered to patients with malaria, and sulfadoxine-pyrimethamine treatment was
used for chloroquine-resistant infections.
Blood samples for immunological analysis and parasitological examination
were collected from each cohort member, after an informed consent was ob-
tained, in regular surveys at the beginning (September) and after the end (Jan-
uary) of annual malaria seasons. The present study included samples collected
during these surveys of 1991 to 1995, including the period of severe drought
(September 1991 to January 1992). Samples were also donated by some cohort
members at the time when they presented with a clinical case of P. falciparum
malaria (which was then treated) during the 1992 to 1994 seasons. Samples from
these patients in subsequent January surveys were taken 1 to 3.5 months (me-
dian, 75 days) after the episodes of clinical malaria. In 1994, 12 patients agreed
to donate an additional convalescent sample 30 to 40 days after their clinical
malaria. Samples from patients during an additional survey in November 1995
were collected 8 to 40 days after clinical malaria. In addition, dry-season samples
were collected in June of 1994 and 1995. A total of 499 plasma samples from 53
individuals were analyzed by enzyme-linked immunosorbent assay (ELISA) for
anti-RAP1 antibody.
In addition to examination of Giemsa-stained blood films, PCRs were per-
formed as described previously (39) to detect P. falciparum in the blood of the
cohort members from September 1993 onward.
rRAP1 antigens. A schematic representation of six rRAP1 proteins derived
from P. falciparum RAP1 is shown in Fig. 1. Glutathione S-transferase (GST)
and hexahistidine (His6) rRAP1 antigens were expressed in Escherichia coli,
purified, and used to evaluate anti-RAP1 antibody responses. The production
and detailed immunological characterization of these rRAP1 antigens have been
described elsewhere (13). The GST protein alone and coating buffer were used
as controls for GST- and His6-RAP1 fusion proteins, respectively.
ELISA for detection of IgG antibodies. All sera were aliquoted and stored at
270°C before use. ELISA procedures were as described elsewhere (13). Briefly,
rRAP1 or control antigens were diluted in coating buffer (0.015 M Na2CO3,
0.035 M NaHCO3, pH 9.6) to a concentration of 0.5 mg/ml. Wells of 96-well
flat-bottomed microtiter plates (Immunolon 4; Dynatech, Billingshurst, United
Kingdom) were coated with 100 ml (50 ng/well) of an antigen at 4°C overnight.
Antigen-coated wells were washed three times with 0.05% (vol/vol) Tween 20 in
phosphate-buffered saline and blocked with 200 ml of 1% (wt/vol) nonfat dried
skimmed milk in phosphate-buffered saline–Tween (blocking buffer) per well for
5 h at room temperature. Human sera were diluted in the blocking buffer for 5 h
at room temperature, and 100-ml aliquots of each diluted serum were added to
duplicate wells for each antigen or control and reacted at 4°C overnight. The
wells were washed as described above and incubated with 100 ml of horseradish
peroxidase-conjugated rabbit anti-human IgG (Dako Ltd., High Wycombe,
United Kingdom) per well diluted 1:5,000, for 3 h at room temperature. The
wells were washed four times, and reactions were developed with 100 ml of
substrate buffer (0.024 M citric acid, 0.05 M Na2HPO4, 0.4 mg of o-phenylene-
diamine [Sigma, Poole, Dorset, United Kingdom] per ml, 0.4 ml of 30% [wt/vol]
H2O2 per ml) per well for 10 min. The reactions were stopped with 20 ml of 2 M
H2SO4 per well, and the optical density (OD) values were read at 492 nm.
Specific reactivity due to the RAP1 portion of GST-RAP1 proteins was ob-
tained by subtraction of averaged OD due to GST alone from averaged OD for
each GST-RAP1 protein. Likewise, for His6 proteins reactivity due to RAP1 was
obtained by subtracting averaged OD due to coating buffer from averaged OD
for P2, P3, P4, or P5 protein. All sera were tested at a dilution of 1:500. This
dilution was chosen after optimization of the assay for specificity with titrations
of sera from malaria-exposed and European donors, rRAP1, and antigen con-
trols (GST or coating buffer). Thus diluted, .95% of endemic serum samples
give low background with the controls. The assay differentiates well between
RAP1 antibody-negative and -positive sera and, within limits, between levels of
antibodies in the positive sera.
Control sera. Negative control sera were collected from 33 healthy European
donors to the Scottish Blood Transfusion Service who had not been exposed to
malaria. A cutoff ELISA OD value for each recombinant protein was calculated
as the mean plus 2 standard deviations of 33 European control serum samples.
The cutoff values were 0.219 for C1, 0.142 for C2, 0.176 for P2, 0.233 for P3, 0.252
for P4, and 0.207 for P5.
A positive standard was a pool of sera from adult Gambians immune to
malaria. Titration of the standard was performed against each antigen in each
experiment to control for interexperimental variation. Titration curves of the
positive standard (dilutions of 1:500, 1:1,000, 1:2,000, 1:4,000, and 1:8,000) were
also used to determine whether antibody levels increased significantly (fourfold
or more) between pretransmission samples and acute malaria and/or posttrans-
mission and/or postinfection samples of each individual. To do this, longitudinal
sets of sera (1:500) from each individual were all tested together at one time.
Titration curves of the standard were produced at the same time, and OD values
obtained for sera of one individual were compared by extrapolation to the
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standard curve. The working range of the assay, between negative cutoff and OD
2.0, is covered within an 8- to 16-fold change in antibody concentration.
ELISA for IgM antibodies. Four rRAP1 proteins (C1, C2, P4, and P5) repre-
senting different regions of P. falciparum RAP1 were used to screen plasmas for
IgM antibodies. The procedure for determining specific anti-RAP1 IgM anti-
bodies was similar to that described above for IgG except that horseradish
peroxidase-conjugated rabbit anti-human IgM (Dako Ltd.) diluted 1:2,000 was
used for detecting IgM antibodies. A cutoff value for each rRAP1 protein in the
IgM assays was calculated as the mean plus 2 standard deviations of 10 normal
European serum samples: 0.096 for C1, 0.092 for C2, 0.206 for P4, and 0.077 for
P5. Since there was no RAP1-specific IgM antibody standard, the anti-IgM
serum was tested in each experiment against a range of concentrations of purified
IgM myeloma protein applied as a coating on plates; the serum reliably detected
between 1 and 0.03 mg of IgM per well.
RESULTS
Longitudinal IgG antibody responses to RAP1 in the cohort.
rRAP1 proteins were used to monitor antibody responses to
P. falciparum RAP1 in a cohort of 53 individuals from 1991 to
1995. Results obtained with a total of 499 serum samples with
three rRAP1 antigens are represented schematically in Fig. 2
(panels a to c correspond to reactivities with antigens C1, P3,
and P5, respectively). First, the reactivity of each tested serum
was compared to a cutoff level of normal European sera. Sec-
ond, to estimate whether and, if so, when antibody responses
occurred for the individuals studied, changes in the strength of
reactivities between pairs of serial serum samples from each
individual were assessed by comparisons to titration curves of
a positive standard serum against each rRAP1 protein. In an
individual, a significant antibody response was defined as a
fourfold or higher increase in serum antibody levels from a
pretransmission season sample (September) to an acute sam-
ple and/or to a posttransmission sample (January).
After 2 years of drought (1989 to 1991), low-positive reac-
tions very close to European negative cutoff values were de-
tected in sera of some individuals between September 1991
and September 1992 (with proteins P3 and P5, illustrated by
Fig. 2b and c, respectively). However, none of the 53 individ-
uals had any significant increase of antibody levels (i.e., re-
sponse) to RAP1 up to September 1992, and this result corre-
lated well with the observed absence of malaria cases during
the drought.
During the autumn of 1992, when malaria transmission re-
started after the return of rains, 14 individuals in the cohort
had a clinical episode of P. falciparum malaria (Fig. 2). Serum
samples from 13 individuals, for whom both September 1992
and postinfection (January 1993) samples were available, were
analyzed for increases in anti-RAP1 levels following the infec-
tions (Table 1). Only 3 to 5 of the 13 individuals had significant
antibody responses detectable with different rRAP1 proteins.
The number of clinical malaria cases increased in the 1993–
1994 and 1994–1995 malaria seasons. Of 26 individuals who
became clinically infected in 1993–1994, 23 individuals donated
pre- and postinfection samples used for the analysis of re-
sponse and 30 to 39% had IgG antibody responses detected
with the rRAP1 proteins (Table 1). Thirty of 32 individuals
who were diagnosed with clinical malaria in 1994–1995 gave
samples valid for the analysis, and 30 to 33% had an IgG
antibody response detectable with at least one rRAP1 protein.
Individuals without a recent history of clinical malaria had
detectable antibody responses to RAP1 only very rarely (Table
1). In 1992, 2 of 39 such individuals (G10 and F12) had re-
sponses detected with some rRAP1 proteins (Fig. 2). Of 27 and
21 individuals without clinical malaria in the 1993–1994 and
1994–1995 seasons, two individuals (2E5 in 1994 and 2E4 in
1995) had an IgG response to RAP1 (Fig. 2).
These results indicate that individuals usually produce de-
tectable IgG antibody responses to RAP1 only during or after
a clinical malaria episode. This accords with the absence of
detectable antibody responses (and of cases) in the cohort
during the drought and up to September 1992.
Different patterns of anti-RAP1 antibody response to clini-
cal malaria in individuals. During the study (1991 to 1995),
three distinct antibody response patterns were observed among
48 individuals who had at least one episode of documented
clinical malaria. The first pattern consisted of a rapid rise in
anti-RAP1 antibodies that was detectable already during the
clinical infection (for example, see Fig. 3A, Oct-93). Among
seven individuals who donated serum samples before and dur-
ing clinical malaria in 1992–1993, two individuals (X5 and 2B4)
had this rapid response detectable with some rRAP1 proteins.
Of 14 infected individuals who gave preinfection and acute-
malaria samples in the 1993–1994 season, 5 (A6, S4, M5, U2,
and 2D2) had the rapid antibody responses. In the 1994–1995
season, 3 individuals (D8, D4, and 2A5) of 18 who gave suit-
able samples showed the rapid response.
FIG. 1. Schematic representation showing mature P. falciparum RAP1 and rRAP1 proteins. P2 to P5 are proteins fused to hexahistidine tag (n); C1 and C2 are
fused to GST ( ). , region of repeats related to the KSSSPS motif (between amino acid 123 and 164). , cleavage site (between amino acid 190 and 191) of mature
RAP1 to yield p65 fragment (35). 2, inhibitory monoclonal antibody epitope (L202 TPLEELYP210 [16]). , cysteine-rich region (between amino acid 353 and 616).
Amino acid numbering is as in the work of Ridley et al. (37). This figure has been modified from the work of Fonjungo et al. (13).
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The second pattern (example in Fig. 3B, Oct-92 infection)
was where no antibody response was seen at the time of acute
infection but a rise did occur later and was detectable during
convalescence 30 to 40 days after clinical malaria (1994 and
1995 cases) or at the time of the postseason surveys in January.
This was the most commonly observed pattern, and 40% of
individuals had significant antibody responses of this slower
type to one or more episodes of malaria.
FIG. 2. Reactivity profiles of IgG antibodies detectable with rRAP1 proteins C1 (a), P3 (b), and P5 (c) in 499 serum samples donated by 53 individuals between
1991 and 1995. Each serum sample was tested by ELISA at a dilution of 1:500, and reactions were developed with peroxidase-conjugated rabbit anti-human IgG diluted
1:5,000. Cutoff levels (means 1 2 standard deviations of 33 European serum samples) and the indicated range of OD values above the cutoffs were used to grade
arbitrarily the strength of each reaction. h, below cutoff level;_, above cutoff (OD , 0.5); , above cutoff (OD 5 0.5 to 1.0); n, above cutoff (OD . 1.0); #,
clinical malaria infection with no available plasma sample; Conv, convalescence sample collected 30 to 40 days after clinical malaria infection.
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The third pattern was characterized by no detectable IgG
antibody response to RAP1 following a documented clinical
infection (example in Fig. 3C, Oct-94). A surprisingly high
proportion of the cohort were in this category at one time or
another over the period of the study (Table 1). More than 60%
of individuals appeared to have failed to respond to at least
one episode of clinical malaria in the three malaria seasons. In
the 1992 season, 8 of 13 individuals with clinical infections had
no antibody response detectable by any rRAP1 protein. In
1993–1994 and 1994–1995, 14 of 23 and 20 of 30 infected
individuals, respectively, had no detectable antibody response.
We have attempted to find whether there is an immunolog-
FIG. 2—Continued.
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ical memory to RAP1 by monitoring IgG responses of individ-
uals who had two or more clinical infections during the study
after the drought. In comparing the first and subsequent in-
fections after the drought, boosting of anti-RAP1 antibody
response was observed in some but not all individuals. An ex-
ample of an apparent boosting is illustrated by Fig. 3B, show-
ing antibody responses of an individual who had a higher re-
sponse to a second infection (Nov-93) than to a previous infection
(Oct-92). Of four individuals with a second infection in 1993–
1994, only one (A6) showed a higher antibody response to the
second infection. In 1994–1995, 2 (X5 and D8) of 11 individ-
uals with a reinfection had a higher antibody response to their
FIG. 2—Continued.
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second than to the first infection. However, other individuals
appeared to have failed to respond well to two infections (e.g.,
AE7, 2J6, 2M4, E2, AE3, and V6). Thus, with repeated infec-
tions a degree of immunological memory to RAP1 may develop,
though this is found relatively infrequently in this cohort.
Patterns of anti-RAP1 antibody response in individuals with-
out malaria. In individuals without clinical malaria, two pat-
terns of antibody response were observed. No detectable anti-
body responses in the absence of any documented malarial
infection throughout the 1991 to 1995 study were observed in
only 3 of the 53 individuals (2A7, D5, and 2I2) (example in Fig.
3D).
The second, more interesting pattern was seen for a few
individuals who had no clinical malaria near the time of a
significant antibody response (example in Fig. 3E). This rarest
pattern was observed for four individuals (G10 and F12 in
1992–1993, 2E5 in 1993–1994, and 2E4 in 1994–1995). These
individuals may have responded while infected asymptomati-
cally. PCR analysis confirmed the presence of P. falciparum in
the blood of two individuals who remained well (example in
Fig. 3E, positive PCR in Jan-95).
The findings support the overall conclusion that the pres-
ence of malarial parasites is required to elicit a specific RAP1
antibody response (and also support the specificity of anti-
RAP1 IgG ELISAs).
Duration of IgG antibody response to RAP1. One of the
objectives of this longitudinal study was to determine how long
anti-RAP1 antibody responses last after an infection. A gen-
erally rapid decline of the responses is illustrated by examples
shown in Fig. 3 and 4. Following a documented malarial infec-
tion at the peak of the transmission season (October or No-
vember), antibodies sometimes persisted until a regular Janu-
ary survey (e.g., Fig. 3B, Nov-93 to Jan-94; Fig. 4, individual
U2) but usually declined to low or undetectable levels by Jan-
uary (e.g., Fig. 3A, Oct-93 to Jan-94; Fig. 4, individuals D8 and
S4). In some cases, responses detected during a malarial in-
fection in September or October waned even by the time of
collection of convalescent samples in November (e.g., Fig. 4,
individuals D4, D7, and D8). Of 10 individuals who had a
significant response to clinical malaria in October, 5 had no
detectable antibody by January. In comparison, antibody could
still be detected in January in all of seven individuals who
responded to an acute infection in November. Collections of
serum samples in June of 1994 and 1995 enabled us to monitor
the duration of antibody response over the dry season. In the
cohort of 53 individuals, no new antibody responses were de-
tected between January and the start of the next malaria sea-
son (e.g., Fig. 3A and B, Jan-94 to Sep-94). Instead, antibodies
detectable in January declined by June in the majority of in-
dividuals from whom both samples were available in 1994 or in
1995 (Fig. 2). Thus, by the start of each of three consecutive
malaria seasons (September of 1993, 1994, and 1995), all but a
few individuals had very low or not detectable IgG antibodies
(Fig. 2). The finding of four individuals with high levels of
antibodies in September of 1994 and 1995 could be explained
by the fact that three of the four cases were infected (PCR
positive), probably due to the earlier onset of malaria trans-
mission in these comparatively wet years (49a).
Together, these results show that the duration of antibody
responses to P. falciparum RAP1 is approximately 2 months or
less in the absence of reinfection or persistence of the infec-
tion.
IgM antibody response to RAP1. In any one season, 61 to
70% of individuals who experienced clinical malaria had no
detectable anti-RAP1 IgG response. We have therefore tested
whether such individuals might be producing IgM antibodies to
RAP1. To investigate this, 33 IgG-negative postinfection sam-
ples were screened for the presence of IgM antibodies with
four rRAP1 proteins, C1, C2, P4, and P5, which are represen-
tative of different parts of the RAP1 protein. No specific IgM
was detected in any of the samples with any of the proteins
(data not shown). Thus, RAP1 IgG-negative samples also had
no detectable RAP1 IgM antibodies.
DISCUSSION
To study the longitudinal kinetics of antibody responses to
RAP1, we have taken advantage of two epidemiological fea-
tures of P. falciparum malaria in Daraweesh (11, 12, 39, 40, 50).
Firstly, Daraweesh has a short and well-defined malaria trans-
mission season, and this allows a reasonably accurate timing of
antibody responses to RAP1 relative to the infection. Sec-
ondly, the main part of the study was initiated after a 2-year
drought period that produced in each individual a low baseline
antibody level to which it was possible to compare antibody
responses after infections in subsequent transmission seasons.
Anti-RAP1 responses of a cohort of 53 permanent residents
were monitored over 4 years, and the results led to the follow-
ing conclusions. (i) Most individuals without a documented
malaria episode had anti-RAP1 levels no higher than those of
nonexposed European controls. (ii) After the 1989 to 1991
drought, anti-RAP1 antibody responses were observed in the
cohort only when transmission and clinical malaria cases reap-
peared in 1992. Individuals had detectable responses to RAP1
usually only after a documented malarial infection. (iii) Anti-
RAP1 antibody response was boostable in at least some indi-
viduals, and this indicates that immunological memory to
RAP1 may develop after a repeated exposure to the parasite.
(iv) However, antibody responses to RAP1 were generally very
short-lived.
Several observations strongly indicate that antigenic stimu-
lation by live malarial infection is required for a sustained
production of RAP1 IgG antibodies. Firstly, no rise in antibody
levels to RAP1 was detected in any cohort member using
samples collected until September 1992. This correlated well
with the absence of malaria during 2 years of drought that
preceded the restart of transmission in September 1992. Also,
no infected mosquitoes were reported in the Daraweesh area
during the drought period (12). Secondly, antibody responses
to RAP1 began to occur only after the first postdrought ma-
laria season (1992–1993), usually only in cases of clinical ma-
laria (Table 1). Thirdly, antibody responses to clinical malaria
declined rapidly after drug treatment of the patients, presum-
TABLE 1. Antibody response to RAP1 in the Daraweesh cohort
Antigen
Antibody response by season [no. positive/
no. total (%)] for individualsa
With clinically documented
malarial infection
Without clinical
malaria
1992–1993 1993–1994 1994–1995 1992–1993 1993–1994 1994–1995
C1 3/13 (23) 7/23 (30) 10/30 (33) 1/39 (3) 1/27 (4) 1/21 (5)
C2 5/13 (38) 7/23 (30) 9/30 (30) 1/39 (3) 0/27 (0) 0/21 (0)
P2 5/13 (38) 9/23 (39) 9/30 (30) 2/39 (5) 1/27 (4) 1/21 (5)
P3 5/13 (28) 9/23 (39) 9/30 (30) 2/39 (5) 1/27 (4) 1/21 (5)
P4 5/13 (38) 9/23 (39) 9/30 (30) 2/39 (5) 1/27 (4) 1/21 (5)
P5 5/13 (38) 9/23 (39) 9/30 (30) 1/39 (3) 1/27 (4) 0/21 (0)
a Response was defined as a fourfold or higher increase in antibody level from
a level detected in a pretransmission sample (September) to a level in an acute-
malaria and/or posttransmission sample (January). Analysis was performed for
those individuals with pre- and posttransmission season samples.
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ably because clearance of the parasites or a decrease in para-
site density resulted in a diminished antigenic stimulation of
the immune response.
RAP1 antibody response was apparently boostable in some
individuals who had a higher IgG antibody response to a sec-
ond infection than to the first documented clinical infection
after the drought. This observation indicates that immunolog-
ical memory to RAP1 can be retained for some time after an
infection. The observation is supported by the report of Stow-
ers and colleagues (46) that two volunteers experimentally
challenged with sporozoites of P. falciparum showed a boosting
effect of a second infection on RAP1 response. Changes in
immune responses of the study cohort probably occurred dur-
ing the drought while P. falciparum malaria was absent for 2
years. During the 1992 to 1994 transmission seasons, 23 to 39%
of individuals with clinical malaria responded to the infection
by production of RAP1 antibodies but only nine individuals
responded rapidly to their first infection after the drought. This
suggested that these individuals had been infected before the
drought and that some retained a degree of immunological
memory despite the lack of transmission for 2 years. This is
somewhat reminiscent of a study in the central highlands of
Madagascar which showed that some older people retained
immunological memory to P. falciparum 155/RESA or circum-
sporozoite protein (CSP) following 20 years of absence of
malaria transmission (6).
FIG. 3. Different patterns of IgG antibody responses to RAP1 in natural
P. falciparum infections. Each panel illustrates the time course of response(s) of
one individual as detected by ELISA with six rRAP1 proteins. The x axes show
the month and the year when each test sample was collected. Dates of samples
collected during documented episodes of clinical malaria are underlined. PCR
results, also along the x axes, indicate the absence (2) or presence (1) of
P. falciparum in blood samples of each individual. nd, PCR was not done.
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It was quite unexpected to find a high percentage of indi-
viduals with clinical malaria who had no detectable IgG anti-
body response. Between 61 and 70% of individuals apparently
failed to respond by production of IgG RAP1 antibodies to the
infection at some time. It is unlikely that all these individuals
had never been exposed to malaria before the drought, since
about 30% of residents of Daraweesh had a confirmed clinical
malarial infection before the interruption of malaria transmis-
sion (50). One explanation may be that a substantial decline in
immunological memory had occurred during the 2 years of the
drought in many individuals, who thus produced only transient
responses or undetectably low levels of antibodies to their
postdrought infections.
Failing to detect RAP1 IgG antibodies after infections in
some individuals, we investigated whether these individuals
produced IgM antibodies to RAP1. No IgM antibody was
detected in 33 IgG-negative serum samples tested. However,
since no specific anti-RAP1 IgM positive control serum was
available, it is not clear whether our IgM assay was sensitive
enough, and the presence of anti-RAP1 IgM responses thus
has not been totally excluded.
Several different hypothetical explanations have been of-
fered by others to account for an apparent failure to produce
antibodies to a defined antigen after a malarial infection. An-
tigenic polymorphism is a common feature of malarial para-
sites (4, 29, 30, 43, 47) that could explain low frequencies of
responses to certain antigens. Priming of individuals to epi-
topes of a highly polymorphic antigen, e.g., block 2 of MSP1,
following exposure to one P. falciparum “strain” may not be
adequate to produce a response on exposure to different epi-
topes of another “strain” (5). However, antigenic polymor-
phism is not likely to account for the apparent lack of response
to RAP1, since RAP1 is a largely conserved protein (17, 19, 20,
37) and the same or similar epitopes are likely to be presented
on every reinfection with P. falciparum.
An intrinsically poor immunogenicity of a malarial antigen
could lead to a lack of or low and undetectable antibody re-
sponse. For example, a relatively high percentage of children
living in an area where malaria is endemic did not have de-
tectable anti-P. falciparum CSP antibodies, while at the same
time producing high titers of antibody to P. falciparum asexual
blood-stage antigens (48). The RAP1 protein could contact
antigen-presenting cells, though probably only transiently due
to its intracellular location, if it was released during merozoite
invasion. Previous studies have shown RAP1 to be poorly sol-
uble in an aqueous environment due to its chemical structure
(7, 37). Thus, it can be envisaged that a reduced exposure,
uptake, processing, or presentation of RAP1 by antigen-pre-
senting cells could result from the poor solubility of RAP1
when released in an aqueous physiological environment. How-
ever, studies carried out in different areas of endemicity (13,
19, 22–25, 46) indicate that, overall, RAP1 is strongly immu-
nogenic, with up to 86% of individuals having antibodies to
RAP1 in some populations. Thus, poor immunogenicity of
RAP1 is an unlikely explanation for the failure to detect anti-
bodies to it in many members of our cohort.
Responses to some malarial antigens can be genetically con-
trolled, and this could result in permanently weak responses or
nonresponsiveness of some individuals. The hypothesis is sup-
ported by studies with inbred mice showing that a failure to
produce antibodies is linked to the H-2 genotype in some
models (27). Strains of mice with the H-2k haplotype produced
antibodies, while H-2b haplotype mice failed to respond or
responded weakly to P. falciparum 155/RESA and peptides
derived from RESA. Also, when mice were immunized with
(NANP)40 repeats of the CSP of P. falciparum, only H-2
b mice
responded while non-H-2b mice were consistently nonrespon-
sive (9). Immunological nonresponsiveness or low responses to
defined malarial antigens such as CSP (14, 34, 44) or P. falci-
parum 155/RESA, 230-kDa, 48/45-kDa and 25-kDa proteins
(34, 38), or the SPf66 vaccine (33) have been reported for
individuals from different areas where malaria is endemic. The
idea of HLA-dependent restriction of immune responses in
humans has been proposed to account for the apparent lack of
or low antibody levels to malarial antigens in some individuals
(14).
The notion of genetic restriction of immune response to
RAP1 has not been investigated here; nonetheless, the results
deserve comments regarding this. Some cohort members who
failed to respond to RAP1 in one infection had an antibody
response upon reinfection or vice versa. Genetic restriction
cannot easily explain the apparent lack of RAP1 response to
one P. falciparum infection and the presence of the response to
another episode of the same infection in the same individual.
However, seven individuals did not produce RAP1-IgG anti-
bodies even after a reinfection, though some of these individ-
uals did respond to other malarial antigens such as MSP1 (5)
or MSP2 (unpublished data). Thus, we do not entirely exclude
a possibility that responsiveness to RAP1 might be genetically
restricted.
FIG. 4. IgG responses to RAP1 are short-lived after recovery from P. falciparum infection. Reactivities of rRAP1 antigens with IgG in sera donated by five different
individuals on the indicated dates before, during, and after drug-cured clinical malarial episodes (asterisks) are shown. Note a rapid decline of antibody levels in all
cases. A cutoff value indicated by a horizontal line is that of P4; cutoffs for the other antigens were lower (see Materials and Methods).
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The most plausible explanation for the lack of detectable
antibody after some malarial episodes is the very short dura-
tion of anti-RAP1 IgG responses in this cohort. This has been
highlighted by the rapid decline of antibody levels during each
dry season, the levels becoming undetectable before the start
of the next malaria season in the majority of individuals who
responded in the previous season (examples in Fig. 3A and B).
In many individuals, antibody responses induced by a clinical
infection in September or October declined to preinfection
levels and were no longer detectable by January. In some cases,
responses detected during a malarial episode waned even by
the time of collection of convalescent samples 1 to 2 months
later (examples in Fig. 4). The short duration of anti-RAP1
antibody response, 2 months or less, can best explain why no
antibodies were detected in convalescent or posttransmission
samples following many infections in this cohort. Antibody
responses to RAP1 in two immunologically naive volunteers
experimentally challenged with P. falciparum sporozoites were
also found to be short-lived (46).
In conclusion, our observations strongly indicate that the
presence of parasites is required first to elicit and then to
maintain anti-RAP1 antibody response. So far, sampling of the
cohort has not been sufficiently frequent to allow a definitive
conclusion on the overall frequency of anti-RAP1 responses
that are of short duration in this population. Interestingly, all
of the few individuals who were found to be infected asymp-
tomatically had antibody responses to RAP1. The finding of
anti-RAP1 responses in such individuals agrees with a report
of Elhassan and colleagues (12), who found other antimalarial
antibodies in individuals with subpatent infections in this pop-
ulation. If antibodies to RAP1 contribute to acquired immu-
nity, the very short duration of the response could have im-
portant implications, as drug treatment of malaria could lead
to a rapid loss of immunity in individuals in this area of unsta-
ble transmission. These issues should be resolved by our cur-
rent, more intensive follow-up studies of clinical cases and also
of asymptomatic infections.
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